Is there an obesity paradox after percutaneous coronary intervention in the contemporary era?: An analysis from a multicenter australian registry

JACC: Cardiovascular Interventions

Volumn 3, Issue 6, 2010, Pages 660-668

  Lancefield, Terase ^a   Clark, David J ^a   Andrianopoulos, Nick ^b   Brennan, Angela L ^b   Reid, Christopher M ^b   Johns, Jennifer ^a   Freeman, Melanie ^a   Charter, Kerrie ^a   Duffy, Stephen J ^c   Ajani, Andrew E ^d,e   Proietto, Joseph ^a,e   Farouque, Omar ^a,e  

^a AUSTIN HEALTH   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

body mass index; obesity paradox; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; WARFARIN; CARDIOVASCULAR AGENT;

ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; AGED; AUSTRALIA; CARDIOVASCULAR DISEASE; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; REGISTER; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BODY MASS INDEX; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; FEMALE; HOSPITAL MORTALITY; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; OBESITY; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; VICTORIA;

EID: 78049441468     PISSN: 19368798     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcin.2010.03.018     Document Type: Article

References (32)

1. World Health Organisation. Obesity and Overweight. Fact sheet Number 311. 2006. Available at: http://www.who.int/mediacentre/ factsheets/fs311/en/index. html. Accessed May 13, 2009.
2. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation 1983;67: 968-77.
3. Key TJ, Allen NE, Spencer EA, Travis RC. The effect of diet on risk of cancer. Lancet 2002;360:861-8.
4. Adams KF, Schatzkin A, Harris TB, et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006;355:763-78.
5. Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med 2007;120: 863-70.
6. Diercks DB, Roe MT, Mulgund J, et al. The obesity paradox in non-ST-segment elevation acute coronary syndromes: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association Guidelines Quality Improvement Initiative. Am Heart J 2006;152:140-8.
7. Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med 2005;165:55-61.
8. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr 2005;81:543-54.
9. Olsen TS, Dehlendorff C, Petersen HG, Andersen KK. Body mass index and poststroke mortality. Neuroepidemiology 2008;30:93-100.
10. Gurm HS, Brennan DM, Booth J, Tcheng JE, Lincoff AM, Topol EJ. Impact of body mass index on outcome after percutaneous coronary intervention (the obesity paradox). Am J Cardiol 2002;90:42-5.
11. Minutello RM, Chou ET, Hong MK, et al. Impact of body mass index on in-hospital outcomes following percutaneous coronary intervention (report from the New York State Angioplasty Registry). Am J Cardiol 2004;93:1229-32.
12. Ellis SG, Elliott J, Horrigan M, Raymond RE, Howell G. Low-normal or excessive body mass index: newly identified and powerful risk factors for death and other complications with percutaneous coronary intervention. Am J Cardiol 1996;78:642-6.
13. Gruberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:578-84.
14. Oreopoulos A, Padwal R, Norris CM, Mullen JC, Pretorius V, Kalantar-Zadeh K. Effect of obesity on short-and long-term mortality postcoronary revascularization: a meta-analysis. Obesity 2008;16:442-50.
15. Powell BD, Lennon RJ, Lerman A, et al. Association of body mass index with outcome after percutaneous coronary intervention. Am J Cardiol 2003;91:472-6.
16. Gruberg L, Mercado N, Milo S, et al. Impact of body mass index on the outcome of patients with multivessel disease randomized to either coronary artery bypass grafting or stenting in the ARTS trial: the obesity paradox II? Am J Cardiol 2005;95:439-44.
17. Steinberg BA, Cannon CP, Hernandez AF, Pan W, Peterson ED, Fonarow GC. Medical therapies and invasive treatments for coronary artery disease by body mass: the "obesity paradox" in the Get With The Guidelines database. Am J Cardiol 2007;100:1331-5.
18. Ajani AE, Reid CM, Duffy SJ, et al. Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry. Med J Aust 2008;189:423-8.
19. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-19.
20. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
21. Jaber WA, Lennon RJ, Mathew V, Holmes DR Jr., Lerman A, Rihal CS. Application of evidence-based medical therapy is associated with improved outcomes after percutaneous coronary intervention and is a valid quality indicator. J Am Coll Cardiol 2005;46:1473-8.
22. Yan AT, Yan RT, Tan M, et al. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome. Am Heart J 2007;154:1108-15.
23. King SB III, Smith SC Jr., Hirshfeld JW Jr., et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2008;51:172-209.
24. Kennedy LMA, Anker SD, Kjekshus J, Cook TJ, Willenheimer R. Impact of neurohormonal blockade on association between body mass index and mortality. Int J Cardiol 2007;119:33-40.
25. Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9.
26. Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, Kurth T. Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol 2008;52:605-15.
27. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-52.
28. Gurm HS, Whitlow PL, Kip KE. The impact of body mass index on short-and long-term outcomes inpatients undergoing coronary revas-cularization: insights from the bypass angioplasty revascularization investigation (BARI). J Am Coll Cardiol 2002;39:834-40.
29. O'Connor NJ, Morton JR, Birkmeyer JD, Olmstead EM, O'Connor GT. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Circulation 1996;93:652-5.
30. Wallace AM, McMahon AD, Packard CJ, et al. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 2001;104:3052-6.
31. Hoefle G, Saely CH, Risch L, et al. Leptin, leptin soluble receptor and coronary atherosclerosis. Eur J Clin Invest 2007;37:629-36.
32. Momin AU, Melikian NM, Shah AM, et al. Leptin is an endothelial- independent vasodilator in humans with coronary artery disease: evidence for tissue specificity of leptin resistance. Eur Heart J 2006;27: 2294-9.